{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-009047","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2024-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.010775+00:00","generated_at":"2026-06-04T09:06:16.104972+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Moleculin reports FY2023 net loss of $29.8M; cash runway into Q4 2024","bullets":["Net loss $29.8M for fiscal year ended Dec 31, 2023; no revenue reported (pre-revenue biotech).","R&D expenses $19.5M, up $0.5M YoY driven by $1.5M WPD sublicense termination; G&A $10.0M, down $1.5M.","Cash and equivalents $23.6M at year-end; management expects runway into Q4 2024.","Closed $4.5M registered direct offering and private placement with institutional investor and insiders.","Positive interim Annamycin data in AML; plans to advance into pivotal Phase 2B/3 trial in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-009047","json":"https://secwatch.observer/filing/0001437749-24-009047.json","markdown":"https://secwatch.observer/filing/0001437749-24-009047.md","text":"https://secwatch.observer/filing/0001437749-24-009047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774924009047/0001437749-24-009047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774924009047/mbrx20240321_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:06:16.104972+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bfd93e786ad3290b3f1db5aa6f75907a9654595f","claim":"Moleculin Biotech, Inc. reported the fiscal year ended December 31, 2023 results: net income $29.8 million.","evidence_excerpt":"Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today reported its financial results for the fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774924009047/0001437749-24-009047-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Net income","value":"$29.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}